+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
BAFNAPH

Bafna Pharmaceuticals Share Price

 
Stock Hit Upper Circuit

 

Bafna Pharmaceuticals live price: ₹168.19. It opened at ₹163 vs previous close ₹160; intraday high/low: ₹168/₹161. The 50 & 200 DMA stand at ₹144.29/₹129.23.

Bafna Pharmaceuticals Performance

  • Today's Low
  • ₹161
  • Today's High
  • ₹168
  • 52 Week Low
  • ₹73
  • 52 Week High
  • ₹213
  • Open Price₹163
  • Previous Close₹160
  • Volume13,861
  • 50 DMA₹144.29
  • 100 DMA₹137.10
  • 200 DMA₹129.23

Bafna Pharmaceuticals Chart

Investment Returns

  • Over 1 Month + 23.81%
  • Over 3 Month + 33.55%
  • Over 6 Month + 12.37%
  • Over 1 Year + 125.76%

Smart Investing Starts Here Start SIP with Bafna Pharmaceuticals for Steady Growth!

Invest Now

Bafna Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 35.8
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 398
  • P/B Ratio
  • 4.1
  • Average True Range
  • 10.67
  • EPS
  • 4.69
  • Dividend Yield
  • 0
  • MACD Signal
  • 7.59
  • RSI
  • 54.73
  • MFI
  • 46.66

Latest Stock News Updates

Bafna Pharma Standalone December 2021 Net Sales at Rs 20.46 crore, up 17.08% Y-o-Y

NULL

In talks with MNCs pharma cos for acquisition of brands: Bafna pharma

Pharmaceuticals formulations major Bafna Pharmaceuticals Ltd was in advanced stage of discussion with some multi-national pharma companies for acquisitions of brands, a company official said.

Bafna Pharma Standalone June 2021 Net Sales at Rs 21.26 crore, up 27.28% Y-o-Y

NULL

Bafna Pharmaceuticals Financials

Bafna Pharmaceuticals Technicals

EMA & SMA

Current Price
₹168.19
+ 8 (4.99%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹155.20
  • 50 Day
  • ₹144.30
  • 100 Day
  • ₹137.10
  • 200 Day
  • ₹129.20

Resistance and Support

158.75 Pivot Speed
  • R3 171.59
  • R2 166.83
  • R1 163.51
  • S1 155.43
  • S2 150.67
  • S3 147.35

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Bafna Pharmaceuticals has an operating revenue of Rs. 150.62 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 7% is okay, ROE of 11% is good. The company has a reasonable debt to equity of 18%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 12% and 16% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 59 which is a POOR score indicating inconsistency in earnings, a RS Rating of 88 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 60 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Bafna Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-05-29 Audited Results
2026-02-11 Quarterly Results
2025-11-11 Quarterly Results
2025-08-12 Quarterly Results
2025-05-26 Audited Results

Bafna Pharmaceuticals Shareholding Pattern

75%
9.34%
12.12%
3.54%

Bafna Pharmaceuticals FAQs

Bafna Pharmaceuticals share price is ₹168 As on 22 June, 2026 | 10:17

The Market Cap of Bafna Pharmaceuticals is ₹397.9 Cr As on 22 June, 2026 | 10:17

The P/E ratio of Bafna Pharmaceuticals is 35.8 As on 22 June, 2026 | 10:17

The PB ratio of Bafna Pharmaceuticals is 4.1 As on 22 June, 2026 | 10:17

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23